Essai d'innocuité et d'efficacité des associations d'epcoritamab chez des sujets atteints de lymphome non hodgkinien à cellules B (LNH-B) (EPCORE™ NHL-2)
Un essai ouvert de phase 1b/2 pour évaluer l'innocuité et l'efficacité préliminaire de l'epcoritamab (GEN3013 ; DuoBody®-CD3xCD20) en association avec d'autres agents chez des sujets atteints de lymphome non hodgkinien (LNH-B) à cellules B
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied.
Trial details include:
- The treatment duration for each participant depends upon which arm of treatment they are assigned to.
- The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks.
- All participants will receive active drug; no one will be given placebo.
Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned.
Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Biologique: Epcoritamab
- Médicament: Rituximab and Lenalidomide
- Médicament: rituximab and bendamustine
- Médicament: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin
- Médicament: gemcitabine and oxaliplatin
- Médicament: rituximab and lenalidomide
- Médicament: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone
- Médicament: Lenalidomide
- Médicament: rituximab, ifosfamide, carboplatin, and etoposide phosphate
Description détaillée
A Phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab in combination with other standard of care (SOC) agents in participants with B-NHL.
All participants in the trial will receive epcoritamab, as monotherapy or in combination. The following regimens will be investigated:
- Arm 1: epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in participants with previously untreated diffuse large B-cell lymphoma (DLBCL)
- Arm 2: epcoritamab + rituximab and lenalidomide (R2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL)
- Arm 3: epcoritamab + rituximab and bendamustine (BR) in participants with previously untreated FL
- Arm 4: epcoritamab + rituximab, cytarabine, dexamethasone, and oxaliplatin/ carboplatin (R-DHAX/C) in participants with R/R DLBCL eligible for autologous stem cell transplant (ASCT)
- Arm 5: epcoritamab + gemcitabine and oxaliplatin (GemOx) in participants with R/R DLBCL ineligible for ASCT due to age, performance status (PS), or comorbidity
- Arm 6: epcoritamab + R2 in participants with previously untreated FL
- Arm 7: epcoritamab maintenance in participants with FL who achieve a complete response (CR) or a partial response (PR) following first or second line SOC treatment
- Arm 8: epcoritamab + reduced dose of R-CHOP (R mini-CHOP) in participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline
- Arm 9: epcoritamab + lenalidomide for second-line treatment in participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy
- Arm 10: epcoritamab + rituximab, ifosfamide, carboplatin, and etoposide phosphate (R-ICE) in participants with R/R DLBCL eligible for ASCT
The trial consists of two parts: Part 1 ('Dose Escalation') and Part 2 ('Dose Expansion'). The primary objective of Part 1 is safety, and it includes Arm 1-5 and Arm 10. Part 2 includes all 10 arms (Arm 1-10) and the primary goal of all arms, except Arm 7, is preliminary efficacy. For Arm 7, the primary goal is safety. Participants in Arm 1-5 and Arm 10 can only participate in either Part 1 or Part 2. Dose Limiting Toxicities (DLTs) will be assessed in Part 1 and for a selected number of participants in Arm 8 during a 28-day period (safety run-in). The arms are conducted in parallel.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
- La phase 1
Accès étendu
Contacts et emplacements
Lieux d'étude
-
-
-
Heidelberg, Australie, VIC 3084
- Austin Health
-
Nedlands, Australie, 6009
- Linear Clinical Research Limited
-
-
-
-
-
Bruges, Belgique, 8000
- AZ Sint-Jan
-
Ghent, Belgique, 9000
- Universitair Ziekenhuis Gent
-
Yvoir, Belgique, 5530
- CHU UCL Namur Site Godinne
-
-
-
-
-
Aarhus, Danemark
- Århus Hospital
-
Copenhagen, Danemark, 2100
- Rigshospitalet
-
Odense, Danemark
- Odense University Hospital
-
Vejle, Danemark
- Vejle Sygehus
-
-
-
-
-
Barcelona, Espagne, 8035
- Hospital Universitari Vall d'Hebron
-
Barcelona, Espagne, 08908
- ICO l Hospitalet
-
Madrid, Espagne, 28046
- Hospital Universitario La Paz
-
Madrid, Espagne, 28040
- Hospital Universitario Fundacion Jimenez Diaz
-
Salamanca, Espagne, 37007
- Hospital Universitario de Salamanca
-
-
-
-
-
Kuopio, Finlande, 70210
- Kuopio University Hospital
-
Lahti, Finlande, 15850
- HUS Cancer Center
-
-
-
-
-
Lille, France, 59037
- Hopital Claude Huriez - CHRU Lille
-
Marseille, France, 13005
- Hôpital de la Timone
-
Paris, France, 75475
- Hôpital Saint-Louis
-
Pierre-Bénite, France, 69495
- Centre Hospitalier Lyon Sud
-
-
-
-
-
Bergamo, Italie, 24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna, Italie
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS
-
Candiolo, Italie, 10060
- Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS
-
Meldola, Italie, 47014
- IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST
-
Milan, Italie, 20122
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
-
Pavia, Italie, 27100
- Fondazione IRCCS Policlinico San Matteo
-
Reggio Emilia, Italie, 42123
- Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia
-
-
-
-
-
Oslo, Norvège, 310
- Oslo Universitetssykehus HF, Radiumhospitalet
-
-
-
-
-
Amsterdam, Pays-Bas, 1105 AZ
- Amsterdam UMC, Locatie VUMC
-
Groningen, Pays-Bas, 9713
- Universitair Medisch Centrum Groningen (UMCG)
-
Leiden, Pays-Bas, 2333 ZA
- Leids Universitair Medisch Centrum
-
Maastricht, Pays-Bas, 6229 HX
- Maastricht University Medical Center
-
Rotterdam, Pays-Bas
- Erasmus Medisch Centrum
-
Utrecht, Pays-Bas, 3584
- UMC Utrecht
-
-
-
-
-
Manchester, Royaume-Uni
- The Christie Hospital
-
Newcastle upon Tyne, Royaume-Uni, NE7 7D
- Freeman Hospital
-
Plymouth, Royaume-Uni, PL6 8DH
- Derriford Hospital
-
-
-
-
-
Borås, Suède
- Södra Älvsborgs Sjukhus
-
Gothenburg, Suède, 413 45
- Sahlgrenska Sjukhuset
-
Lund, Suède
- Skånes Universitetssjukhus
-
Solna, Suède
- Karolinska Universitetssjukhuset
-
Uppsala, Suède
- Akademiska Sjukhuset
-
-
-
-
-
Hradec Králové, Tchéquie
- Fakultni nemocnice Hradec Kralove
-
Ostrava - Poruba, Tchéquie
- Fakultni nemocnice Ostrava
-
Prague, Tchéquie, 15006
- Fakultni nemocnice v Motole
-
Prague, Tchéquie
- Vseobecna Fakultni Nemocnice
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama at Birmingham
-
-
California
-
Los Angeles, California, États-Unis, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, États-Unis, 90095
- David Geffen School of Medicine at UCLA
-
San Francisco, California, États-Unis, 94143
- University of California San Francisco
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan Comprehensive Cancer Center Michigan Medicine
-
-
New Jersey
-
Hackensack, New Jersey, États-Unis, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, États-Unis, 10029
- Mount Sinai
-
New York, New York, États-Unis, 10065
- Memorial Sloan Kettering CC
-
-
North Carolina
-
Charlotte, North Carolina, États-Unis, 28204
- Levine Cancer Center
-
-
Texas
-
Dallas, Texas, États-Unis, 75390
- Southwestern Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria
- Measurable disease defined as ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI). Applies to all arms except arm 7.
- Eastern Cooperative Oncology Group (ECOG) PS score of 0, 1 or 2
- Acceptable organ function at screening
- CD20-positive non-Hodgkin lymphoma (NHL) at most recent representative tumor biopsy
- If of childbearing potential participant must practicing a highly effective method of birth control
- A man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control
Arm 1:
- Newly diagnosed DLBCL
- DLBCL, not otherwise specified (NOS)
- "Double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Arm 2: R/R FL
Arm 3: Newly diagnosed, previously untreated FL grade 1-3A
Arm 4:
- Documented R/R DLBCL and eligible for HDT-ASCT
- DLBCL, NOS
- "Double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Arm 5:
- Documented R/R DLBCL and ineligible for HDT-ASCT
- DLBCL, NOS
- "Double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Arm 6: Newly diagnosed, previously untreated FL grade 1-3A
Arm 7:
- FL Grade 1-3A
- If PR or CR per Lugano criteria following first-line or second-line treatment with SOC regimen, and last dose of SOC within 6 months prior to enrollment.
Arm 8:
- Newly diagnosed DLBCL who are not fit to receive full-dose anthracycline
- T-cell/histiocyte rich DLBCL
- "Double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Arm 9:
- R/R FL
- Progressed within 24 months of initiating first-line treatment
Arm 10:
- Documented R/R DLBCL and eligible for HDT-ASCT
- DLBCL, NOS
- "Double-hit" or "triple-hit" DLBCL
- FL Grade 3B
Key Exclusion Criteria
- Chemotherapy, radiation therapy, or major surgery within 4 weeks prior to the first dose of epcoritamab
- Any prior treatment with a bispecific antibody targeting CD3 and CD20.
- Treatment with CAR-T therapy within 100 days prior to first dose of epcoritamab
- Clinically significant cardiovascular disease
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
- CNS lymphoma or known CNS involvement by lymphoma at screening as confirmed by MRI/CT scan of the brain and, if clinically indicated, by lumbar puncture
- Positive tests for hepatitis B virus or hepatitis C virus indicating acute or chronic infection
- Known history of seropositivity of human immunodeficiency virus (HIV)
- Active tuberculosis or history of completed treatment for active tuberculosis within the past 12 months
- Neuropathy > grade 1
- Receiving immunostimulatory agent
- Prior allogeneic HSCT
- Current seizure disorder requiring anti-epileptic therapy
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Arm 1 - Epcoritamab + R-CHOP
In participants with previously untreated DLBCL. |
6 cycles (21-day cycles)
Autres noms:
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
|
|
Expérimental: Arm 2 - Epcoritamab + R2
In participants with R/R FL. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
Rituximab 375 milligrams per meter squared (mg/m^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.
Autres noms:
|
|
Expérimental: Arm 3 - Epcoritamab + BR
In participants with previously untreated FL. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
6 cycles (28-day cycles)
Autres noms:
|
|
Expérimental: Arm 4 - Epcoritamab + R-DHAX/C
In participants with R/R DLBCL eligible for ASCT. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
3 cycles (21-day cycles)
Autres noms:
|
|
Expérimental: Arm 5 - Epcoritamab + GemOx
In participants with R/R DLBCL ineligible ASCT. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
4 cycles (28-day cycles)
Autres noms:
|
|
Expérimental: Arm 6 - Epcoritamab + R2
In participants with previously untreated FL. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)
Autres noms:
|
|
Expérimental: Arm 7 - Epcoritamab maintenance
In participants with FL who achieved a CR or PR after receiving SOC treatment in 1L or 2L. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
|
|
Expérimental: Arm 8 - Epcoritamab + R mini-CHOP
In participants with previously untreated DLBCL who are ineligible to receive full-dose anthracycline. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
6 cycles (21-day cycles)
Autres noms:
|
|
Expérimental: Arm 9 - Epcoritamab + Lenalidomide
In participants with R/R FL who progressed within 24 months of initiation of first-line anti-CD20-containing immunochemotherapy. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
12 cycles (28-day cycles) |
|
Expérimental: Arm 10 - Epcoritamab + R-ICE
In participants with R/R DLBCL eligible for ASCT. |
Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Autres noms:
Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Autres noms:
Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Autres noms:
Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Autres noms:
Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.
Autres noms:
Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.
Autres noms:
Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.
Autres noms:
3 cycles (21-day cycles)
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1: Number of Participants With Dose limiting Toxicities (DLTs)
Délai: During the first cycle (Cycle length= 28 days) in each cohort
|
DLT events are defined as clinically significant adverse events (AEs) or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications as assessed per Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0. |
During the first cycle (Cycle length= 28 days) in each cohort
|
|
Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)
Délai: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
|
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |
From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
|
|
Part 2 (Except Arm 7): Overall Response Rate (ORR)
Délai: Up to 3 years
|
ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on Lugano criteria. |
Up to 3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Partie 1 et 2 : Autorisation (CL) d'epcoritamab
Délai: Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
|
|
Partie 1 et 2 : Concentration plasmatique maximale (pic) (Cmax) d'epcoritamab
Délai: Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
|
|
Parties 1 et 2 : Temps nécessaire pour atteindre la Cmax (Tmax) de l'epcoritamab
Délai: Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
|
|
Parties 1 et 2 : Demi-vie d'élimination terminale (t 1/2) de l'épcoritamab
Délai: Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
Prédose et postdose à plusieurs moments jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
|
|
Parties 1 et 2 : Nombre de participants présentant des anticorps anti-médicament (ADA) contre l'epcoritamab
Délai: Jusqu'à 3 ans
|
Jusqu'à 3 ans
|
|
|
Partie 1 et 2 : Durée de la négativité de la maladie résiduelle minimale (MRM)
Délai: Jusqu'à 3 ans
|
Jusqu'à 3 ans
|
|
|
Partie 2 (bras 7) : Pourcentage de participants qui sont passés de la positivité MRD à la négativité MRD
Délai: Jusqu'à 3 ans
|
Jusqu'à 3 ans
|
|
|
Partie 2 (sauf bras 7) : pourcentage de participants ayant obtenu une réponse complète (RC) dans les bras 1 à 10
Délai: Jusqu'à 3 ans
|
Jusqu'à 3 ans
|
|
|
Partie 1 et 2: zone sous la courbe de concentration (ASC) d'Eporitamab
Délai: Prédose et postdose à plusieurs points de calendrier jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
Prédose et postdose à plusieurs points de calendrier jusqu'à l'arrêt du traitement (jusqu'à 3 ans)
|
|
|
Part 1 and 2: Number of Immune Cell Populations
Délai: Up to 2 years
|
Immune cell populations in peripheral blood and tumor biopsies will be assessed. |
Up to 2 years
|
|
Part 1 and 2: Percentage of Immune Cell Populations
Délai: Up to 2 years
|
Immune cell populations in peripheral blood and tumor biopsies will be assessed. |
Up to 2 years
|
|
Part 1 and 2: Change From Baseline in Cytokine Levels up to Cycle 3
Délai: Up to Cycle 3 (cycle length = 21 days for Arms 1, 4, 8 and 10; cycle length = 28 days for Arms 2, 3, 5, 6 and 9; cycle length = 28 days (Cycle 1) and 56 days (Cycles 2, 3) for Arm 7)
|
Change in cytokine levels in peripheral blood samples will be assessed. |
Up to Cycle 3 (cycle length = 21 days for Arms 1, 4, 8 and 10; cycle length = 28 days for Arms 2, 3, 5, 6 and 9; cycle length = 28 days (Cycle 1) and 56 days (Cycles 2, 3) for Arm 7)
|
|
Part 1 and 2: Change From Baseline in Circulating Tumor Deoxyribonucleic Acid (DNA) Level up to End of Treatment (up to 2 Years)
Délai: Up to 2 years
|
Change in circulating tumor DNA levels will be assessed. |
Up to 2 years
|
|
Part 1: ORR
Délai: Up to 3 years
|
ORR is defined as the percentage of participants achieving CR or PR based on Lugano criteria. |
Up to 3 years
|
|
Part 1 and 2: Duration of Response (DOR)
Délai: Up to 3 years
|
DOR: the time from the first documentation of objective tumor response (CR or PR) to the date of first PD or death, whichever occurs earlier, based on Lugano criteria. |
Up to 3 years
|
|
Part 1 and 2: Time to Response (TTR)
Délai: Up to 3 years
|
TTR is defined as the time from Day 1 of Cycle 1 to first documentation of objective tumor response (CR or PR). |
Up to 3 years
|
|
Part 1 and 2: Progression Free Survival (PFS)
Délai: Up to 3 years
|
PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause, whichever occurs earlier, based on Lugano criteria. |
Up to 3 years
|
|
Part 1 and 2: Overall Survival (OS)
Délai: Up to 3 years
|
OS is defined as the time from the date of first dose, to the date of death due to any cause. |
Up to 3 years
|
|
Part 1 and 2: Time to Next Anti-lymphoma Therapy (TTNT)
Délai: Up to 3 years
|
TTNT is defined as the time from Day 1 of Cycle 1 to first documented administration of subsequent anti-lymphoma therapy. |
Up to 3 years
|
|
Part 1 and 2: Percentage of Participants With Minimal Residual Disease (MRD) Negativity
Délai: Up to 3 years
|
It is defined as the percentage of participants with at least 1 MRD negative result. |
Up to 3 years
|
|
Part 2 (Arm 7): Percentage of Participants With CR
Délai: Week 24, Week 48, and Week 96
|
It is defined as the percentage of participants who remain in complete remission or converting to complete remission after first trial drug administration. |
Week 24, Week 48, and Week 96
|
|
Part 1 and 2: Time to Complete Response (TTCR)
Délai: Up to 3 years
|
TTCR is defined as the time from first trial drug administration to the date of first documented complete response post-treatment. |
Up to 3 years
|
|
Part 1 and 2: Duration of Complete Response (DoCR)
Délai: Up to 3 years
|
DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs first based on Lugano criteria. |
Up to 3 years
|
|
Part 2: Number of Participants with AEs (Except Arm 7)
Délai: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
|
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign. (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |
From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Brody JD, Jorgensen J, Belada D, Costello R, Trneny M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, Andre M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial. Blood. 2025 Apr 10;145(15):1621-1631. doi: 10.1182/blood.2024026830.
- Falchi L, Sureda A, Leppa S, Vermaat JSP, Nijland M, Christensen JH, de Vos S, Holte H, Merryman RW, Lugtenburg PJ, Abrisqueta P, Linton KM, Sunkersett G, Hoehn D, Rana A, Abbas A, Marek J, Hao Y, Steele AJ, Morehouse C, Hutchings M, Belada D. Fixed-duration epcoritamab plus R2 drives favorable outcomes in relapsed or refractory follicular lymphoma. Blood. 2025 Nov 27;146(22):2629-2640. doi: 10.1182/blood.2025029909.
- Falchi L, Vermaat JSP, Brody JD, Leslie L, Offner F, Christensen JH, Nijland M, Belada D, Wahlin BE, Drott K, Gomez Prieto P, Kopeckova K, Garcia-Sancho AM, Mei JP, Altintas I, Risum M, Reilly A, Zou J, Abrisqueta P. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial. Lancet Haematol. 2026 Sep;13(9):e614-e625. doi: 10.1016/S2352-3026(26)00198-5.
- Falchi L, Offner F, de Vos S, Brody JD, Morillo D, Linton K, Snauwaert S, Roost Clausen M, Karimi YH, Thieblemont C, Vitolo U, Leslie LA, Narkhede MS, Cordoba R, Oki T, Wielgos-Bonvallet M, Khoshdeli M, Hao Y, Archer K, Risum M, Belada D. Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial. Blood. 2026 Aug 11:blood.2026033839. doi: 10.1182/blood.2026033839. Online ahead of print.
- Abrisqueta P, Karimi YH, Morillo D, Cordoba R, Phillips T, De Vos S, Nijland M, Offner F, Andersson PO, Brody J, Cheah CY, Prieto PG, Hellstrom M, Jorgensen JM, Lewis D, Linton KM, Musuraca G, Wang L, Marek J, Osei-Bonsu K, Risum M, Falchi L. Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial. Haematologica. 2026 Oct 1;111(10):3346-3357. doi: 10.3324/haematol.2025.300086. Epub 2026 Mar 5.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome non hodgkinien
- Lymphome à cellules B
- Lymphome
- Maladies hémiques et lymphatiques
- Lymphome diffus à grandes cellules B
- Lymphome folliculaire
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Benzimidazoles
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Acides nucléiques, nucléotides et nucléosides
- Hydrocarbures
- Hydrocarbures, cyclique
- Glucides
- Acides, acyclique
- Acides carboxyliques
- Alcaloïdes
- Hydrocarbures aromatiques polycycliques
- Hydrocarbures, aromatique
- Composés polycycliques
- Glycosides
- Pipéridines
- Indoles
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Complexes de coordination
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Prégnades
- Grossesse
- Stéroïdes
- Composés à anneau fusionné
- Stéroïdes, fluorés
- Moutards phosphoramides
- Composés de moutarde d'azote
- Composés moutarde
- Hydrocarbures, halogénés
- Phosphoramides
- Composés organophosphores
- Nucléosides
- Grossissement
- Grossissements
- Alcaloïdes Vinca
- Alcaloïdes de la secologane tryptamine
- Alcaloïdes indole
- Indolizidines
- Indolizines
- Arabinonucléosides
- Anthracyclines
- Naphtacènes
- Aminoglycosides
- Butyrate
- Anticorps, monoclonal et murin
- Daunorubicine
- Oxazines
- Phtalimides
- Acides phtaliques
- Acides, carbocyclique
- Pipéridones
- Isoindoles
- Lénalidomide
- Oxaliplatine
- Chlorhydrate de bendamustine
- Rituximab
- Gemcitabine
- Dexaméthasone
- Prednisone
- Cyclophosphamide
- Cytarabine
- Carboplatine
- Doxorubicine
- Vincristine
- Ifosfamide
- phosphate d'étoposide
- Protocole R-Chop
Autres numéros d'identification d'étude
- GCT3013-02
- 2020-000845-15 (Numéro EudraCT)
- NL74222.056.20 (Identificateur de registre: CCMO)
- 283235 (Autre identifiant: IRAS ID; UK Research Summaries Database)
- RECF4377 (Autre identifiant: The French National Cancer Institute)
- 2023 (Subvention/contrat des NIH des États-Unis)
- 2023-504805-35-00 (Ctis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .